PARP1 and colorectal carcinoma: Here, we provide a rational for the inclusion of the PARP inhibitor Olaparib in two new therapeutic approaches for CRC: (1) in combination with 5-FU for dMMR/MSI CRC and (2) as monotherapy for pMMR/MSS CRC.